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A B S T R A C T
Significance: The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no
known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying
effective therapies.
Objective: The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in
combination with azithromycin in hospitalized patients positive for COVID-19.
Design: Multi-center retrospective observational study.
Setting: The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health
system;the largestofhospitals isan802-bed quaternaryacademicteachinghospital inurbanDetroit,Michigan.
Participants: Consecutive patients hospitalized with a COVID-related admission in the health system from
March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with
multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients
for at least 48 h unless expired within 24 h.
Exposure: Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin,
azithromycin alone, or neither.
Main outcome: The primary outcome was in-hospital mortality.
Results: Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4–10 days), median age
was 64 years (IQR:53–76 years), 51% male, 56% African American, with median time to follow-up of 28.5
days (IQR:3–53). Overall in-hospital mortality was 18.1% (95% CI:16.6%–19.7%); by treatment:
hydroxychloroquine + azithromycin, 157/783 (20.1% [95% CI: 17.3%–23.0%]), hydroxychloroquine alone,
162/1202 (13.5% [95% CI: 11.6%–15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%–30.1%]), and
neither drug, 108/409 (26.4% [95% CI: 22.2%–31.0%]). Primary cause of mortality was respiratory failure
(88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of
mortality were age>65 years (HR:2.6 [95% CI:1.9–3.3]), white race (HR:1.7 [95% CI:1.4–2.1]), CKD (HR:1.7
[95%CI:1.4–2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1–2.1]), and ventilator use
during admission (HR: 2.2 [95%CI:1.4–3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction,
and hydroxychloroquine + azithromycin 71% compared to neither treatment (p < 0.001).
Conclusions and relevance: In this multi-hospital assessment, when controlling for COVID-19 risk factors,
treatment with hydroxychloroquine alone and in combination with azithromycin was associated with
reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
* Corresponding author at: Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI 48202, United States.
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https://doi.org/10.1016/j.ijid.2020.06.099
1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Introduction
As of May 27, 2020, there were over 1,678,843 confirmed cases
of COVID-19 claiming more than 100,000 lives in the Unites States
(CDC, 2020). Currently there is no known effective therapy or
vaccine. The urgent need for therapeutic agents has resulted in
repurposing and redeployment of experimental agents (McCreary
and Pogue, 2020; Sanders et al., 2020).
Hydroxychloroquine, an antimalarial and immunomodulatory
agent and a safer analogue of chloroquine, has demonstrated
antiviral activity against SARS-CoV-2 (Wang et al., 2020a; Liu et al.,
2020; Yao et al., 2020; WHO, 2017). It is postulated to exert a direct
antiviral activity by increasing intracellular pH resulting in
decreased phago-lysosome fusion, impairing viral receptor glyco-
sylation. In addition, it has immune-modulating effect by
inhibiting toll-like receptor signaling, decreasing production of
cytokines especially IL-1 and IL-6 (Savarino et al., 2003). Prior data
also suggests a potential anti-thrombotic effect (Jung et al., 2010).
Azithromycin, a macrolide antibiotic, has in vitro antiviral
properties such as decreased viral replication, blocking entrance
into host cells, and a potential immunomodulating effect (Tran
et al., 2019). An in vitro study demonstrated synergistic activity of
the combination of hydroxychloroquine and azithromycin against
SARS-CoV-2 (Andreani et al., 2020). A small non-randomized,
open-label trial from France reported higher frequency of SARS-
CoV-2 clearance after six days of treatment with hydroxychlor-
oquine alone or hydroxychloroquine in combination with azi-
thromycin versus untreated control group (70% vs 12.5%; P < 0.001)
(Gautret et al., 2020a). Other early studies of hydroxychloroquine
have reported conflicting results (Gao et al., 2020; Gautret et al.,
2020b; Chen et al., 2020a; Tang et al., 2020; Chen et al., 2020b; Yu
et al., 2020; Geleris et al., 2020; Rosenberg et al., 2020; Magagnoli
et al., 2020; Million et al., 2020). The US FDA as of June 15, 2020 has
revoked the prior emergency use authorization (EUA) to use
hydroxychloroquine and chloroquine to treat COVID-19 in certain
hospitalized patients when clinical trial data is unavailable or
participation is not feasible (FDA, 2020).
Currently, randomized trials of hydroxychloroquine for treat-
ment and chemoprophylaxis are underway (NIH, 2020a; NIH,
2020b; NIH, 2020c; Pagliano et al., 2020). Based on these early
reports, hydroxychloroquine alone and in combination with
azithromycin was incorporated into our institutional clinical
guidelines for the treatment of hospitalized patients with
COVID-19. We examined the association between hydroxychlor-




This is a comparative retrospective cohort study evaluating
clinical outcomes of all consecutive patients hospitalized at the
Henry Ford Health System (HFHS) in Southeast Michigan being
treated for COVID-19. The organization is a large six hospital
integrated health system; the largest of hospitals is an 802-bed
quaternary academic teaching hospital in urban Detroit, Michigan.
Approval for this study was granted by the Henry Ford Hospital IRB
(#13897).
Patients
Patients with a COVID-related admission in the health system
from March 10, 2020 to May 2, 2020 were included. Only the first
admission was included for patients with multiple admissions. All
patients were hospitalized though our emergency department. A
COVID-related admission was defined as hospitalization during
which the patient had a positive SARS-CoV-2 test. Diagnosis with
SARS-CoV-2 was confirmed by a positive reverse-transcriptase-
polymerase-chain-reaction (RT-PCR) assay from a nasopharyngeal
sample. All patients evaluated were 18 years of age and older and
were treated as inpatients for at least 48 h unless they died within
the time period. The primary objective was to assess treatment
experience with hydroxychloroquine versus hydroxychloroquine
+ azithromycin, azithromycin alone, and other treatments for
COVID-19. Treatments were protocol driven, uniform in all
hospitals and established by a system-wide interdisciplinary
COVID-19 Task Force. Hydroxychloroquine was dosed as 400 mg
twice daily for 2 doses on day 1, followed by 200 mg twice daily on
days 2–5. Azithromycin was dosed as 500 mg once daily on day 1
followed by 250 mg once daily for the next 4 days. The combination
of hydroxychloroquine + azithromycin was reserved for selected
patients with severe COVID-19 and with minimal cardiac risk
factors. An electrocardiogram (ECK) based algorithm was utilized
for hydroxychloroquine use. QTc > 500 ms was considered an
elevated cardiac risk and consequently hydroxychloroquine was
reserved for patients with severe disease with telemetry monitor-
ing and serial QTc checks. The clinical guidelines included
adjunctive immunomodulatory therapy with corticosteroids and
tocilizumab.
Data sources
The data source for analysis of patient information was derived
from electronic medical records in the Electronic Information
System. Study variables collected on each patient included the
following; (1) patient demographics: age, gender, race, body mass
index (BMI) on admission, stratified into four categories: <18.5;
18.5–24.9; 25.0–29.9 and 30; (2) clinical characteristics: admis-
sion date, discharge date, length of stay (LOS), comorbidities
including: cardiovascular disease (CVD), chronic lung disease,
chronic kidney disease (CKD), hypertension, asthma, chronic
obstructive pulmonary disease (COPD), diabetes mellitus, immu-
nodeficiency, and cancer (defined as active or past/resolved).
Additionally, intensive care unit (ICU) status and ventilator use at
any point during admission, minimum O2 saturation level
collected on day of admission in the emergency department,
and the maximal modified Sequential Organ Failure Assessment
(mSOFA) score on admission were also collected. The mSOFA score
is predictive of ICU mortality utilizing similar accuracy to the full
SOFA score without substantial lab testing (ABG, LFTs) to complete
(Grissom et al., 2010). The duration and dosages of all therapies for
COVID-19 were collected.
Study endpoint
The primary endpoint was in-patient hospital mortality in each
treatment group. All deaths were reviewed in detail by the study
team.
Statistical analysis
Demographic and clinical characteristics were descriptively
summarized for all patients and subsets by treatment group, to test
the null hypothesis that treatment course between hydroxychlor-
oquine, hydroxychloroquine + azithromycin, azithromycin, and
other (no hydroxychloroquine or azithromycin) were similar.
Multivariable Cox regression models and Kaplan–Meier survival
curves were used to compare survival among treatment groups
while controlling for demographics (e.g., age, gender), preexisting
medical conditions (e.g. CVD, lung disease) and clinical disease
severity (mSOFA, O2 saturation). Bivariate comparisons of the 4
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medication groups were made using analysis of variance or
Kruskal–Wallis tests for continuous variables, and chi-square tests
or Fisher exact tests for categorical variables. Additional analysis
was performed using propensity score matching to compare
outcomes in mortality across treatment groups. A propensity score
was created for each patient based on the set of patient
characteristics used in the Cox regression model. Subsequently,
1 to 1 matchups of patients given hydroxychloroquine (either
hydroxychloroquine alone or in combination with azithromycin)
and patients not given hydroxychloroquine based on the exact
propensity score were observed. The resulting matched group
status was placed into its own Cox regression model as a mortality
predictor with a Kaplan–Meier plot summarizing the survival
curves of the two matched groups. P values <0.05 were considered
statistically significant. Additionally, median survival times by
treatment strata were calculated to approximate prognosis. No
imputations were made for missing data. All data were analyzed
using SPSS software version 26 (IBM SPSS Statistics for Windows,
version 26, IBM Corp., Armonk, N.Y., USA) and STATA (StataCorp.
2019. Stata Statistical Software: Release 16. College Station, TX:
StataCorp LLC), and SAS version 9.4.
Results
The first COVID-19 case confirmed at HFHS by RT-PCR was on
March 10, 2020, any patients admitted before March 10th and
subsequently tested positive were also included in the analyses.
There was a total of 2,948 COVID-19 admissions, of these, 267 (9%)
patients had not been discharged, 15 (0.5%) left against medical
advice, and four (0.1%) were transferred to another healthcare
facility; these patients were excluded from analysis as we could not
ascertain their outcome. In addition, there were 121 (4.1%)
readmissions, which were also excluded.
Overall, 2,541 consecutive patients were included in the
analyses with a median age of 64 years (IQR: 53–76 years), 51%
male, 56% African American, median inpatient LOS was 6 days
(IQR: 4–10 days). The median time to follow-up was 28.5 days (IQR
3–53). The majority of patients (52%, n = 1,250) had BMI  30.
Additional underlying comorbidities are detailed in Table 1. On the
day of admission, two variables predicting severity of disease and
mortality, highest mSOFA score and lowest O2 saturation, were
recorded. However, 25% of the population did not have mSOFA
scores available, as recording of this metric became institutional
standard one month after the index admission. Other indicators of
severity were ICU admission and mechanical ventilation status. All
baseline characteristics were further stratified by the four
treatment groups (hydroxychloroquine alone, hydroxychloro-
quine + azithromycin, azithromycin alone, and neither treatment).
Median time (IQR) from admission to receipt of hydroxychlor-
oquine was 1 day (1–2). Overall crude mortality rates were 18.1% in
the entire cohort, 13.5% in the hydroxychloroquine alone group,
20.1% among those receiving hydroxychloroquine + azithromycin,
22.4% among the azithromycin alone group, and 26.4% for neither
drug (p < 0.001). Adjunct therapy with corticosteroids (methyl-
prednisolone and/or prednisone) and anti-IL-6 tocilizumab was
provided in 68% and 4.5% of patients, respectively.
Primary cause of mortality in the 460 patients was: 88%
respiratory failure, 4% cardiac arrest (with mean QTc interval from
last ECG reading 471 ms), 8% other cardiopulmonary arrest and
multi-organ failure. No patient had documented torsades de
pointes.
In the multivariable Cox regression model of mortality using the
group receiving neither hydroxychloroquine or azithromycin as
the reference, treatment with hydroxychloroquine alone de-
creased the mortality hazard ratio by 66% (p < 0.001), and
hydroxychloroquine + azithromycin decreased the mortality
hazard ratio by 71% (p < 0.001). We did not find statistical
significance in the relative effect of adjunct therapy and mortality.
Predictors of mortality were age 65 years (HR, 2.6 [95% CI: 1.9,
3.3]), white race (HR: 1.7 [95% CI: 1.4, 2.1]), CKD (HR, 1.7 [95%CI: 1.4,
2.1]), reduced O2 saturation level on admission (HR, 1.6 [95%CI: 1.1,
2.2]), and ventilator use during admission (HR, 2.2 [95%CI: 1.4,
3.0]), which were all significantly associated with mortality due to
COVID-19 (Table 2).
Kaplan–Meier survival curves showed significantly improved
survival among patients in the hydroxychloroquine alone and
hydroxychloroquine + azithromycin group compared with groups
not receiving hydroxychloroquine and those receiving azithromy-
cin alone (Figure 1). The survival curves suggest that the enhanced
survival in the hydroxychloroquine alone group persists all the way
out to 28 days from admission.
Further, a total of 190 hydroxychloroquine patients exactly
matched up with 190 corresponding non-hydroxychloroquine
treated patients based on the exact underlying propensity score.
Table 3 contains a descriptive summarization of these patients
within both the unmatched and propensity matched settings,
confirming that the propensity matched groups have identical
underlying patient characteristics. The Cox regression result for the
two propensity matched groups (Table 4) indicates that treatment
with hydroxychloroquine resulted in a mortality hazard ratio
decrease of 51% (p = 0.009). The resulting Kaplan–Meier survival
curves within the propensity matched setting displayed signifi-
cantly better survival in the hydroxychloroquine treated group,
with the enhanced survival persisting all the way out to 28 days
from admission (Figure 2).
Discussion
The results of this study demonstrate that in a strictly
monitored protocol-driven in-hospital setting, treatment with
hydroxychloroquine alone and hydroxychloroquine + azithromycin
was associated with a significant reduction in mortality among
patients hospitalized with COVID-19. In this study, among one of
the largest COVID-19 hospital patient cohorts (n = 2,541) assem-
bled in a single institution, overall in-hospital COVID-19 associated
mortality was 18.1% reflecting a high prevalence of co-morbid
conditions in COVID-19 patients admitted to our institution. The
independent predictors of mortality in our study included age 65
years, CKD, and severe illness at initial presentation as measured
by the oxygen saturation levels on admission, and ventilator use
reflect findings similar to those reported in earlier studies (Rio and
Malani, 2020). These predictors also underscore the high-risk for
COVID-19 experienced by residents in our hospital catchment
population in Metropolitan Detroit, Michigan. Michigan is among
the states with the highest number of cases of COVID-19 and
deaths. In Detroit, our residents suffer from substantial preexisting
social and racial health disparities that place our patients at
increased risk of severe disease and higher mortality (CDC, 2020).
In the present study, multivariate analysis performed using Cox
regression modeling and propensity score matching to control for
potential confounders affirmed that treatment with hydroxychlor-
oquine alone and hydroxychloroquine in combination with
azithromycin was associated with higher survival among patients
with COVID-19. Patients that received neither medication or
azithromycin alone had the highest cumulative hazard. The
benefits of hydroxychloroquine in our cohort as compared to
previous studies maybe related to its use early in the disease
course with standardized, and safe dosing, inclusion criteria,
comorbidities, or larger cohort. The postulated pathophysiology of
COVID-19 of the initial viral infection phase followed by the
hyperimmune response suggest potential benefit of early admin-
istration of hydroxychloroquine for its antiviral and antithrombotic
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properties. Later therapy in patients that have already experienced
hyperimmune response or critical illness is less likely to be of
benefit. Others have shown that COVID-19 hospitalized patients
are not diagnosed in the community and often rapidly deteriorate
when hospitalized with fulminant illness (Mc McCullough and
Arunthamakun, 2020).
Limitations to our analysis include the retrospective, non-
randomized, non-blinded study design. Also, information on
duration of symptoms prior to hospitalization was not available
for analysis. However, our study is notable for use of a cohort of
consecutive patients from a multi-hospital institution, regularly
updated and standardized institutional clinical treatment guidelines
and a QTc interval-based algorithm specifically designed to ensure
the safe use of hydroxychloroquine. To mitigate potential limitations
associated with missing or inaccurate documentation in electronic
medical records, we manually reviewed all deaths to confirm the
primary mortality outcome and ascertain the cause of death. A
review of our COVID-19 mortality data demonstrated no major
cardiac arrhythmias; specifically, no torsades de pointes that has
been observed with hydroxychloroquine treatment. This finding
may be explained in two ways. First, our patient population received
aggressive early medical intervention, and were less prone to
development of myocarditis, and cardiac inflammation commonly
seen in later stages of COVID-19 disease. Second, and importantly,
inpatient telemetry with established electrolyte protocols were
stringently applied to our population and monitoring for cardiac
dysrhythmias was effective in controlling for adverse events.
Additional strengths were the inclusion of a multi-racial patient
composition, confirmation of all patients for infection with PCR, and
control for various confounding factors including patient character-
istics such as severity of illness by propensity matching.
Recent observational retrospective studies and randomized
trials of hydroxychloroquine have reported variable results
(Gautret et al., 2020a; Gao et al., 2020; Gautret et al., 2020b;
Chen et al., 2020a; Tang et al., 2020; Chen et al., 2020b; Yu et al.,
2020; Geleris et al., 2020; Rosenberg et al., 2020; Magagnoli et al.,
2020; Million et al., 2020). In a randomized controlled study of 62
patients from China with COVID-19, hydroxychloroquine was
Table 1
Patient characteristics by treatment group.
Characteristics Total (n = 2541) Neither Med (n = 409) HCQ alone (n = 1202) AZM alone (n = 147) HCQ + AZM (n = 783) P-value
Mortality, n (%) 460 (18.1) 108 (26.4) 162 (13.5) 33 (22.4) 157 (20.1) <0.001***
Hospital LOS in days,


























































































































Chronic lung disease, n (%) 1619 (63.7) 195 (47.7) 806 (67.1) 93 (63.3) 525 (67.0) <0.001***
Immunodeficiency, n (%) 30 (1.2) 2 (0.5) 15 (1.2) 2 (1.4) 11 (1.4) 0.502
Cardiovascular disease, n (%) 222 (8.7) 45 (11.0) 100 (8.3) 10 (6.8) 67 (8.6) 0.306
Chronic kidney disease, n (%) 1099 (43.3) 196 (47.9) 528 (43.9) 62 (42.2) 313 (40.0) 0.062
COPD, n (%) 325 (12.8) 58 (14.2) 144 (12.0) 24 (16.3) 99 (12.6) 0.380
Hypertension, n (%) 1663 (65.4) 256 (62.6) 807 (67.1) 93 (63.3) 507 (64.8) 0.324
Asthma, n (%) 251 (9.9) 28 (6.8) 130 (10.8) 19 (12.9) 74 (9.5) 0.069
Cancer, n (%) 380 (15.0) 78 (19.1) 165 (13.7) 17 (11.6) 120 (15.3) 0.041*
Diabetes mellitus, n (%) 955 (37.6) 130 (31.8) 484 (40.3) 45 (30.6) 296 (37.8) 0.006**
Max mSOFA score on admission,


































Max O2 saturation on admission,







































Ever in ICU, n (%) 614 (24.2%) 62 (15.2) 243 (20.2) 19 (12.9) 290 (37.0) <0.001***
Total ICU days,












Ever mechanically ventilated, n (%) 448 (17.6%) 34 (8.3) 166 (13.8) 14 (9.5) 234 (29.9) <0.001***
Total vent days,












Given steroid, n (%) 1733 (68.2) 146 (35.7) 948 (78.9) 57 (38.8) 582 (74.3) <0.001***
Given tocilizumab, n (%) 114 (4.5) 5 (1.2) 32 (2.7) 5 (3.4) 72 (9.2) <0.001***
* P-values between 0.01 and 0.05.
** P-values between 0.001 and 0.01.
*** P-values less than 0.001.
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associated with a shortened duration of fever and time to cough
and pneumonia resolution (Chen et al., 2020b). In contrast, a study
of 1376 consecutive hospitalized COVID-19 patients in New York
that used respiratory failure as the primary endpoint found no
significant reduction in the likelihood of death or intubation
among those receiving hydroxychloroquine compared to those
who did not (Geleris et al., 2020). In a separate multicenter cohort
study of 1438 patients from 25 hospitals in New York, no reduction
in hospitalized patient mortality was observed with hydroxy-
chloroquine treatment (Rosenberg et al., 2020). Among a number
of limitations, this study included patients who were initiated on
hydroxychloroquine therapy at any time during their hospitaliza-
tion. In contrast, in our patient population, 82% received
hydroxychloroquine within the first 24 h of admission, and 91%
within 48 h of admission. Because treatment regimens likely varied
substantially (including delayed initiation) across the 25 hospitals
that contributed patients to the study, it is not surprising that the
case-fatality rate among the New York patients was significantly
higher than in our study.
Globally, the overall crude mortality from SARS-COV-2 is
estimated to be approximately 6–7% (CDC, 2020; WHO, 2020).
Multiple descriptive studies report higher mortality in hospitalized
COVID-19 patients from 10–30% (Huang et al., 2020; Zhou et al.,
2020; Wu et al., 2020; Wang et al., 2020b; Guan et al., 2020;
Richardson et al., 2020; Arentz et al., 2020; Cao et al., 2020; Grein
et al., 2020). Not surprisingly, mortality as high as 58% was
observed among patients requiring ICU care and mechanical
ventilation (Guan et al., 2020; Richardson et al., 2020). This high
Table 2
Multivariable cox regression model for mortality prediction.
Parameter P-value Hazard ratio 95% Hazard ratio confidence limits
HCQ alone (vs. neither medication) <0.001*** 0.340 0.254 0.455
Azithromycin alone (vs. neither medication) 0.825 1.050 0.682 1.616
HCQ + AZM (vs. neither medication) <0.001*** 0.294 0.218 0.396
Age > 65 years <0.001*** 2.579 1.989 3.345
M gender 0.155 1.157 0.946 1.414
White race <0.001*** 1.738 1.413 2.137
BMI > 30 0.021* 0.775 0.624 0.962
Lung comorbidity 0.393 0.908 0.727 1.134
Immunodeficiency comorbidity 0.429 1.398 0.609 3.206
Cardiovascular comorbidity 0.678 1.062 0.800 1.410
Chronic kidney disease comorbidity <0.001*** 1.699 1.370 2.108
COPD comorbidity 0.170 1.202 0.924 1.563
Hypertension comorbidity 0.064 0.798 0.628 1.014
Asthma comorbidity 0.643 0.916 0.632 1.327
Cancer comorbidity 0.577 0.933 0.731 1.190
Diabetes comorbidity 0.822 0.975 0.786 1.211
Percent O2 saturation < 95 0.021* 1.488 1.063 2.084
Admitted to ICU 0.882 0.969 0.635 1.478
Ventilator <0.001*** 2.159 1.427 3.268
Given steroid 0.085 0.802 0.625 1.031
Given tocilizumab 0.490 0.894 0.651 1.228
* P-values between 0.01 and 0.05.
*** P-values less than 0.001.
Figure 1. Kaplan-Meier survival curves among treatment groups.
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mortality associated with COVID-19 in many populations has led to
a search for effective drug therapies. The randomized controlled
trial of lopinavir–ritonavir in COVID-19 hospitalized patients
showed a mortality of 19.2% on lopinavir–ritonavir and 25% for
standard of care; therapy had to be terminated in 13.8% patients
due to adverse events (Arentz et al., 2020). In the compassionate
use remdesivir trial, 13% mortality was observed in the cohort of 61
patients (Cao et al., 2020). The interim analysis randomized trial of
remdesivir showed a mortality rate of 8.0% for the group receiving
remdesivir versus 11.6% for the placebo group (p = 0.059) (Grein
et al., 2020). In our study, overall mortality was 18.1% and in ICU
patients 45%. Our cohort included patients with severe disease,
with 24% and 18% requiring ICU care and mechanical ventilation at
presentation, respectively.
Findings of this observational study provide crucial data on
experience with hydroxychloroquine therapy, providing necessary
interim guidance for COVID-19 therapeutic practice. These findings
do support the recent NIH guidelines (NIH, 2020a), indicating a
potential role for hydroxychloroquine in treatment of hospitalized
COVID-19 patients without co-administration of azithromycin.
However, our results should be interpreted with some caution and
should not be applied to patients treated outside of hospital
settings. Our results also require further confirmation in
Table 3
Characteristics of patients given versus not given HCQ before and after propensity score matching.
Characteristics Unmatched patients Propensity-MATCHED patients
Given HCQ (N = 1985) Not given HCQ (N = 556) Given HCQ (N = 190) Not given HCQ (N = 190)
Age > 65 years 944 (47.6%) 319 (57.4%) 96 (50.5%) 96 (50.5%)
Male gender 1037 (52.2%) 261 (46.9%) 88 (46.3%) 88 (46.3%)
White race 603 (30.4%) 249 (44.8%) 67 (35.3%) 67 (35.3%)
BMI > 30 1035 (55.5%) 215 (40.9%) 87 (45.8%) 87 (45.8%)
Lung comorbidity 1331 (67.1%) 288 (51.8%) 103 (54.2%) 103 (54.2%)
Immunodeficiency comorbidity 26 (1.3%) 4 (0.7%) 1 (0.5%) 1 (0.5%)
Cardiovascular comorbidity 167 (8.4%) 55 (9.9%) 7 (3.7%) 7 (3.7%)
Chronic kidney disease comorbidity 841 (42.4%) 258 (46.4%) 69 (36.3%) 69 (36.3%)
COPD comorbidity 243 (12.2%) 82 (14.7%) 10 (5.3%) 10 (5.3%)
Hypertension comorbidity 1314 (66.2%) 349 (62.8%) 118 (62.1%) 118 (62.1%)
Asthma comorbidity 204 (10.3%) 47 (8.5%) 6 (3.2%) 6 (3.2%)
Cancer comorbidity 285 (14.4%) 95 (17.1%) 8 (4.2%) 8 (4.2%)
Diabetes comorbidity 780 (39.3%) 175 (31.5%) 51 (26.8%) 51 (26.8%)
Percent O2 saturation < 95 1641 (82.7%) 396 (71.2%) 141 (74.2%) 141 (74.2%)
Admitted to ICU 533 (26.9%) 81 (14.6%) 12 (6.3%) 12 (6.3%)
Ventilator 400 (20.2%) 48 (8.6%) 10 (5.3%) 10 (5.3%)
Given steroid 1530 (77.1%) 203 (36.5%) 84 (44.2%) 84 (44.2%)
Given tocilizumab 104 (5.2%) 10 (1.8%) 2 (1.1%) 2 (1.1%)
Table 4
Propensity matched cox regression result for mortality prediction.
Parameter P-value Hazard ratio 95% Hazard ratio confidence limits
Given HCQ 0.009* 0.487 0.285 0.832
* P-value between 0.001 and 0.01.
Figure 2. Kaplan-Meier survival curves within the propensity matched setting.
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prospective, randomized controlled trials that rigorously evaluate
the safety and efficacy of hydroxychloroquine therapy for COVID-
19 in hospitalized patients. Considered in the context of current
studies on the use of hydroxychloroquine for COVID-19, our results
suggest that hydroxychloroquine may have an important role to
play in reducing COVID-19 mortality.
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